(IN BRIEF) Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the Middle East and North Africa—once approved. Vedolizumab treats Crohn’s disease and ulcerative colitis, and PB016 references Takeda’s Entyvio®. The transaction … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Poland, Science, Technology
Tagged #FutureFresenius, (Bio)Pharma portfolio, chronic inflammatory diseases, Crohn's disease, denosumab biosimilar, Dr. Sang-Jin Pak, EC Approval, Entyvio, FDA approval, Fresenius Kabi, global commercialization, Konstantin Matentzoglu, licensing agreement, partnership, PB016, Polpharma Biologics S.A., Ulcerative colitis, Ustekinumab Biosimilar, vedolizumab biosimilar
(IN BRIEF) The European Commission has approved Fresenius Kabi’s denosumab biosimilars, Conexxence® and Bomyntra®, for all uses of the originator product. These include osteoporosis treatment for postmenopausal women and at-risk men, mitigation of treatment-related bone loss, prevention of skeletal complications … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged #FutureFresenius, Biopharma platform, Bomyntra, cancer metastasis to bone, Conexxence, denosumab biosimilar, Europe, European Commission approval, Fresenius, Fresenius Kabi, Fresenius Kabi Deutschland GmbH, giant cell tumor of bone, high-quality biosimilars, osteoporosis, postmenopausal women, registered trademarks, skeletal complications, treatment-related bone loss
(IN BRIEF) Fresenius Management SE has extended Sara Hennicken’s term as Chief Financial Officer (CFO) until 2027, two years earlier than planned, to ensure continuity in advancing the #FutureFresenius strategy. Hennicken, who joined Fresenius in 2019, has been instrumental in … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Management, Pharma & Biotech, Technology
Tagged #FutureFresenius, CFO, Chief Financial Officer, Deutsche Bank, finance, Fresenius, Fresenius Helios, Fresenius Kabi, Fresenius Management SE, Fresenius Medical Care, Sara Hennicken, Supervisory Board, transparency, Wolfgang Kirsch
(IN BRIEF) Fresenius Kabi announces FDA approval of Tyenne® (tocilizumab-aazg), the first tocilizumab biosimilar offering both IV and subcutaneous formulations. This marks a significant milestone in the company’s growth strategy (#FutureFresenius) and expands treatment options for inflammatory, autoimmune diseases, and … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged #FutureFresenius, Actemra®, autoimmune diseases, Biosimilar, Cancer, cancer treatment, FDA, Food and Drug Administration, Fresenius Kabi, Genentech, Idacio®, inflammatory, inflammatory diseases, IV, IV formulation, Stimufend®, Subcutaneous formulation, subcutaneous tocilizumab biosimilar, tocilizumab, tocilizumab biosimilar, tocilizumab-aazg, Tyenne®
(IN BRIEF) Fresenius had a strong finish in 2023, with a robust fourth quarter performance. They project accelerated earnings growth in 2024 due to the momentum from their #FutureFresenius initiatives. Achieving their raised outlook for FY/23, the company saw continued … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?